SI
IRON icon

Saxon Interests’s Disc Medicine IRON Stock Holding History

Saxon Interests’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,576
Closed -$205K – 234
2025
Q4 		$205K Buy
+2,576
New +$218K 0.07% 201

Other funds holding IRON

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Saxon Interests's IRON Position: Q1 2026 in Review

Saxon Interests sold out of Disc Medicine (IRON) in Q1 2026, closing a stake of 2,576 shares — an estimated $205K sold.

Saxon Interests first reported a position in IRON in Q4 2025 and held it in 1 quarter. The position peaked at $205K in Q4 2025. 203 funds tracked by Wall St. Rank hold IRON as of Q1 2026.

  • Saxon Interests reported no remaining Disc Medicine position as of Q1 2026 after selling out during the quarter.
  • Saxon Interests sold 2,576 Disc Medicine shares in Q1 2026, an estimated $205K.
  • Saxon Interests first reported a position in Disc Medicine in Q4 2025 and held it in 1 quarter.
  • Saxon Interests's Disc Medicine position peaked at $205K in Q4 2025.
  • 203 funds tracked by Wall St. Rank held Disc Medicine as of Q1 2026.

Based on Saxon Interests's 13F filing for Q1 2026, filed 29 Apr 2026.